

# Takami Sato

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8244453/publications.pdf>

Version: 2024-02-01

77  
papers

2,860  
citations

201385

27  
h-index

182168

51  
g-index

79  
all docs

79  
docs citations

79  
times ranked

3409  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. JAMA - Journal of the American Medical Association, 2014, 311, 2397.	3.8	359
2	CHECKPOINT INHIBITOR IMMUNE THERAPY. Retina, 2018, 38, 1063-1078.	1.0	252
3	Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunologic Research, 2011, 51, 170-182.	1.3	215
4	Protracted survival after resection of metastatic uveal melanoma. Cancer, 2000, 89, 1561-1568.	2.0	138
5	Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Research, 2005, 15, 297-304.	0.6	116
6	Radioembolization as Salvage Therapy for Hepatic Metastasis of Uveal Melanoma: A Single-Institution Experience. American Journal of Roentgenology, 2011, 196, 468-473.	1.0	111
7	Locoregional Management of Hepatic Metastasis From Primary Uveal Melanoma. Seminars in Oncology, 2010, 37, 127-138.	0.8	84
8	Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Clinical Oncology, 2008, 26, 5436-5442.	0.8	83
9	A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Research, 2012, 22, 440-446.	0.6	76
10	Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte-Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases. Journal of Vascular and Interventional Radiology, 2015, 26, 523-532.e2.	0.2	70
11	Effects of Oncogenic G $\beta$ q and G $\beta$ 11 Inhibition by FR900359 in Uveal Melanoma. Molecular Cancer Research, 2019, 17, 963-973.	1.5	68
12	PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy, 2017, 9, 1323-1330.	1.0	64
13	Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Research, 2015, 75, 2737-2748.	0.4	57
14	Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Molecular Cancer Therapeutics, 2017, 16, 516-528.	1.9	55
15	Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma. Ophthalmology, 2018, 125, 210-217.	2.5	53
16	Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Molecular Medicine, 2019, 11, .	3.3	49
17	Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. , 2019, 7, 104.		43
18	Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell and Melanoma Research, 2014, 27, 297-308.	1.5	42

#	ARTICLE	IF	CITATIONS
19	A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. <i>Radiology</i> , 2019, 293, 223-231.	3.6	42
20	First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. <i>Oncologist</i> , 2019, 24, e930-e942.	1.9	41
21	Paclitaxel and tamoxifen. , 2000, 88, 79-87.		39
22	The biology and management of uveal melanoma. <i>Current Oncology Reports</i> , 2008, 10, 431-438.	1.8	38
23	Transhepatic Therapies for Metastatic Uveal Melanoma. <i>Seminars in Interventional Radiology</i> , 2013, 30, 039-048.	0.3	38
24	Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. <i>EBioMedicine</i> , 2015, 2, 1821-1826.	2.7	38
25	IsomiRs and tRNA-derived fragments are associated with metastasis and patient survival in uveal melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 52-62.	1.5	37
26	Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 3190-3200.	3.2	35
27	Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis. <i>Journal of Translational Medicine</i> , 2017, 15, 145.	1.8	33
28	Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 145-155.	2.0	32
29	Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea. <i>American Journal of Roentgenology</i> , 2015, 205, 429-433.	1.0	31
30	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1939-1948.	0.8	29
31	Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 405.	1.7	28
32	BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. <i>Oncogene</i> , 2021, 40, 618-632.	2.6	28
33	Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 14428-14442.	0.8	27
34	Melanoma and vitiligo: immunology's Grecian urn. <i>Cancer Immunology, Immunotherapy</i> , 1996, 42, 263-267.	2.0	26
35	Locoregional immuno(bio)therapy for liver metastases. <i>Seminars in Oncology</i> , 2002, 29, 160-167.	0.8	25
36	An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. <i>Cancers</i> , 2020, 12, 117.	1.7	25

#	ARTICLE	IF	CITATIONS
37	Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).. Journal of Clinical Oncology, 2013, 31, CRA9003-CRA9003.	0.8	25
38	Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. Molecular Cancer Therapeutics, 2020, 19, 1719-1726.	1.9	22
39	Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. American Journal of Pathology, 2016, 186, 43-56.	1.9	20
40	Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). Future Oncology, 2016, 12, 751-762.	1.1	18
41	Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma. Journal of Translational Medicine, 2020, 18, 208.	1.8	18
42	Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.. Journal of Clinical Oncology, 2017, 35, 9531-9531.	0.8	18
43	Genetic Landscape and Emerging Therapies in Uveal Melanoma. Cancers, 2021, 13, 5503.	1.7	17
44	The Role of HGF/MET Signaling in Metastatic Uveal Melanoma. Cancers, 2021, 13, 5457.	1.7	15
45	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 3990-4002.	3.2	15
46	Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunology, Immunotherapy, 2004, 53, 53-61.	2.0	13
47	Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine. Cancer Immunology, Immunotherapy, 1996, 43, 174-179.	2.0	12
48	Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes. CardioVascular and Interventional Radiology, 2017, 40, 1392-1400.	0.9	12
49	A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. Melanoma Research, 2020, 30, 574-579.	0.6	12
50	Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. Journal of Biological Chemistry, 2021, 297, 101033.	1.6	12
51	Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).. Journal of Clinical Oncology, 2013, 31, CRA9003-CRA9003.	0.8	12
52	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 439-445.	1.2	10
53	Prognostic Values of G-Protein Mutations in Metastatic Uveal Melanoma. Cancers, 2021, 13, 5749.	1.7	10
54	Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma. Cancers, 2021, 13, 1104.	1.7	8

#	ARTICLE	IF	CITATIONS
55	Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma.. Journal of Clinical Oncology, 2016, 34, 9541-9541.	0.8	7
56	A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.. Journal of Clinical Oncology, 2020, 38, e22059-e22059.	0.8	7
57	Abstract 1137: PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells. Cancer Research, 2021, 81, 1137-1137.	0.4	6
58	Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. , 2021, 9, e003272.		6
59	Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. American Journal of Surgery, 2017, 214, 884-890.	0.9	5
60	Resolution of pre-cancerous and non-melanoma skin cancers after immune checkpoint inhibitor treatments.. Journal of Clinical Oncology, 2016, 34, e14540-e14540.	0.8	5
61	Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice. Journal of Visualized Experiments, 2019, , .	0.2	4
62	Unique Geospatial Accumulations of Uveal Melanoma. American Journal of Ophthalmology, 2020, 220, 102-109.	1.7	4
63	Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: Regression of pulmonary metastases. , 2001, 94, 531.		4
64	Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).. Journal of Clinical Oncology, 2019, 37, 9592-9592.	0.8	4
65	Improved Uveal Melanoma Copy Number Subtypes Including an Ultra-High-Risk Group. Ophthalmology Science, 2022, 2, 100121.	1.0	4
66	Orthotopic Human Metastatic Uveal Melanoma Xenograft Mouse Models: Applications for Understanding the Pathophysiology and Therapeutic Management of Metastatic Uveal Melanoma. Current Protocols, 2021, 1, e110.	1.3	3
67	Potential survival benefit of adjuvant sunitinib in high risk uveal melanoma.. Journal of Clinical Oncology, 2015, 33, e20046-e20046.	0.8	1
68	Thyroid-related laboratory abnormalities to predict treatment-limiting adverse events in melanoma patients treated with immune checkpoint blockade.. Journal of Clinical Oncology, 2016, 34, e14536-e14536.	0.8	1
69	Circulating cell free DNA to predict recurrence in uveal melanoma.. Journal of Clinical Oncology, 2016, 34, 9569-9569.	0.8	1
70	Tumor Necrosis Factor- $\alpha$ Blockade and Development of Uveal Melanoma: Expected Adverse Effect or Just Coincidence?. Mayo Clinic Proceedings, 2014, 89, 1467-1470.	1.4	0
71	Adjuvant sunitinib in high-risk patients with uveal melanoma: A pilot study.. Journal of Clinical Oncology, 2012, 30, 8560-8560.	0.8	0
72	Correlation of caveolin 1 expression with disease-free survival in skin melanoma.. Journal of Clinical Oncology, 2012, 30, e19016-e19016.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Development of renal cell carcinoma in patients with primary uveal melanoma.. Journal of Clinical Oncology, 2013, 31, e15563-e15563.	0.8	0
74	High-Dose Vincristine Sulfate Liposome Injection (Marqibo®) Is Not Associated With Clinically Meaningful Hematologic Toxicity. Blood, 2013, 122, 2676-2676.	0.6	0
75	Unique clustering of uveal melanoma in young females.. Journal of Clinical Oncology, 2015, 33, e20054-e20054.	0.8	0
76	Combination treatment with ipilimumab and immunoembolization in metastatic uveal melanoma: A feasibility study.. Journal of Clinical Oncology, 2015, 33, e20015-e20015.	0.8	0
77	Effects of Oncogenic G $\beta$ q and G $\beta$ 11 Inhibition by FR900359 in Uveal Melanoma. FASEB Journal, 2019, 33, 815.9.	0.2	0